{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:31:14Z","timestamp":1766788274081,"version":"3.41.2"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI) treatment has dramatically revolutionized the landscape of therapeutic approaches in multiple cancers, particularly, non-small-cell lung cancer (NSCLC). With the increasing use of programmed death-1 (PD-1) inhibitors in the clinic, the emerging toxicity profile presents a novel learning curve for clinicians. Here we report the first case of an NSCLC patient displaying sarcoid\/granulomatous-like reaction (SLR, also known as GLR) in the liver during an anti-PD-1 therapy which showed efficacious response of complete regression. Also, this is the first report describing the SLR induced by toripalimab, a novel PD-1 inhibitor. Given this kind of hepatic findings can be easily mistaken as metastasis, even resulting in premature use of second-line treatments. In particular, we briefly review the clinical features of all those cases reporting sarcoidosis and SLRs manifested on different organs during anti-PD-(L)1 therapy. We anticipate that these clinical cases would help to alert the attention of clinicians that SLRs, as a rare immune-related adverse event (irAE), is manageable and that histopathological analysis is necessary before interpreting it as disease progression.<\/jats:p>","DOI":"10.3389\/fonc.2022.824308","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T14:31:08Z","timestamp":1646922668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuxin","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyin","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca-Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-Small-Cell Lung Cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-Small Cell Lung Cancer: Current Treatment and Future Advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Trans Lung Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and Pemetrexed With or Without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet (London England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa054","article-title":"A Randomized Phase III Study Comparing Continuation and Discontinuation of PD-1 Pathway Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer (JCOG1701, SAVE Study)","volume":"50","author":"Nomura","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in Combination With Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared With Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01127","article-title":"Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma","volume":"11","author":"Shui","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13770","article-title":"Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial","volume":"3","author":"Wang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-Related Adverse Events With Immune Checkpoint Blockade: A Comprehensive Review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.07.010","article-title":"Pembrolizumab Reactivates Pulmonary Granulomatosis","volume":"22","author":"Al-Dliw","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-Related Cutaneous Sarcoidosis in a Patient With Lung Adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","article-title":"Sarcoidosis in the Setting of Combination Ipilimumab and Nivolumab Immunotherapy: A Case Report & Review of the Literature","volume":"4","author":"Reuss","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40425-018-0372-4","article-title":"Thoracic and Cutaneous Sarcoid-Like Reaction Associated With Anti-PD-1 Therapy: Longitudinal Monitoring of PD-1 and PD-L1 Expression After Stopping Treatment","volume":"6","author":"Paolini","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000298","article-title":"Sarcoid-Like Reaction Discovered on EBUS-TBNA of Intrathoracic Lymph Nodes During Immunotherapy for Metastatic Melanoma","volume":"43","author":"Frohlich","year":"2020","journal-title":"J Immunother (Hagerstown Md: 1997)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01490-2","article-title":"Immune Checkpoint Inhibitor-Induced Sarcoidosis-Like Granulomas","volume":"24","author":"Rambhia","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.954506","article-title":"Late Development of Splenic Sarcoidosis-Like Lesions in a Patient With Metastatic Melanoma and Long-Lasting Clinical Response to Ipilimumab","volume":"3","author":"Andersen","year":"2014","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000362614","article-title":"New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient With Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment","volume":"37","author":"Murphy","year":"2014","journal-title":"Oncol Res Treat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12380","article-title":"Cutaneous Sarcoidosis in a Melanoma Patient Under Ipilimumab Therapy","volume":"29","author":"Mart\u00ednez Lebor\u00e1ns","year":"2016","journal-title":"Dermatol Ther"},{"key":"B23","article-title":"Sarcoidosis in a Patient With Metastatic Melanoma Sequentially Treated With Anti-CTLA-4 Monoclonal Antibody and Selective BRAF Inhibitor","volume":"32","author":"Wilgenhof","year":"2012","journal-title":"Anticancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and Pulmonary Sarcoidosis-Like Reaction Associated With Ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.humpath.2019.07.001","article-title":"Immune Checkpoint Blocker-Related Sarcoid-Like Granulomatous Inflammation: A Rare Adverse Event Detected in Lymph Node Aspiration Cytology of Patients Treated for Advanced Malignant Melanoma","volume":"91","author":"Rodriguez","year":"2019","journal-title":"Hum Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1200\/JCO.2011.37.9693","article-title":"Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission","volume":"30","author":"Vogel","year":"2012","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"20190065","DOI":"10.1259\/bjrcr.20190065","article-title":"Sarcoidosis-Like Disease Mimicking Metastases During Adjuvant Ipilimumab Therapy in Advanced Melanoma Patient: CT Scan and MRI Help in Managing Difficult Clinical Decision","volume":"6","author":"Garanzini","year":"2020","journal-title":"BJR Case Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-Like Lesions Associated With Checkpoint Inhibitors: A Marker of Therapy Response in a Subset of Melanoma Patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-Like Syndrome and Lymphadenopathy Due to Checkpoint Inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000181","article-title":"Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma","volume":"40","author":"Reddy","year":"2017","journal-title":"J Immunother (Hagerstown Md: 1997)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018180572","article-title":"Pembrolizumab-Induced Sarcoid-Like Reactions During Treatment of Metastatic Melanoma","volume":"289","author":"Cheshire","year":"2018","journal-title":"Radiology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002779","article-title":"18f-FDG PET\/CT of Multiorgan Sarcoid-Like Reaction During Anti-PD-1 Treatment for Melanoma","volume":"44","author":"van Willigen","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.027383","article-title":"Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars","volume":"14","author":"McKenna","year":"2018","journal-title":"J Oncol Pract"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S1470-2045(18)30252-3","article-title":"Checkpoint Inhibitor-Induced Sarcoid Reaction Mimicking Bone Metastases","volume":"19","author":"Jespersen","year":"2018","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000680","article-title":"An Atypical Sarcoid-Like Reaction During Anti-Protein Death 1 Treatment in a Patient With Metastatic Melanoma","volume":"30","author":"Keukeleire","year":"2020","journal-title":"Melanoma Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001066","article-title":"Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma","volume":"40","author":"Woodbeck","year":"2018","journal-title":"Am J Dermatopathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-Induced Sarcoidosis in Patients With Melanoma Treated With PD-1 Checkpoint Inhibitors: Case Series and Immunophenotypic Analysis","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.remnie.2020.09.004","article-title":"Subcutaneous Sarcoidosis Induced by Pembrolizumab in a Melanoma Patient Mimicking Subcutaneous Metastasis at 18F-FDG PET\/Ct","volume":"40","author":"Marcoval","year":"2020","journal-title":"Rev Esp Med Nucl  Imagen Mol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2017.11.008","article-title":"Sarcoidosis Post-Anti-PD-1 Therapy, Mimicking Relapse of Metastatic Melanoma in a Patient Undergoing Complete Remission","volume":"39","author":"Yatim","year":"2018","journal-title":"La Rev Med Interne"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2016.12.014","article-title":"Multifocal Choroiditis as the First Sign of Systemic Sarcoidosis Associated With Pembrolizumab","volume":"5","author":"Lise","year":"2016","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002408","article-title":"FDG PET\/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis","volume":"44","author":"Lu","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14781","article-title":"Programmed Cell Death 1 Blockade-Induced Cutaneous Sarcoid-Like Epithelioid Granulomas in Advanced Melanoma: A Case Report","volume":"32","author":"Ogawa","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418776934","article-title":"Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction","volume":"22","author":"Laroche","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14887","article-title":"Sarcoid-Like Reaction and Vitiligo Occurring After Nivolumab Therapy in a Patient With Metastatic Melanoma","volume":"46","author":"Fukuchi","year":"2019","journal-title":"J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13569","article-title":"Granulomatous\/sarcoid-Like Reactions in the Setting of Programmed Cell Death-1 Inhibition: A Potential Mimic of Disease Recurrence","volume":"47","author":"Hiraki","year":"2020","journal-title":"J Cutan Pathol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"100652","DOI":"10.1016\/j.ajoc.2020.100652","article-title":"Checkpoint Inhibitor-Induced Sarcoid Choroidal Granulomas","volume":"18","author":"Ung","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary Sarcoid-Like Granulomatosis Induced by Nivolumab","volume":"176","author":"Montaudi\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002724","article-title":"Nivolumab-Associated Pulmonary and Bone Sarcoidosis in a Patient With Melanoma of Unknown Primary","volume":"44","author":"Tulbah","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001227","article-title":"Cutaneous and Pulmonary Sarcoid-Like Reaction Induced by Nivolumab: Case Report and Brief Literature Review","volume":"27","author":"Urrego-Callejas","year":"2019","journal-title":"J Clin Rheumatol: Pract Rep Rheum Musculoskeletal Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e14618","DOI":"10.1111\/dth.14618","article-title":"Challenges in Sarcoidosis and Sarcoid-Like Reactions Associated to Immune Checkpoint Inhibitors: A Narrative Review Apropos of a Case","volume":"34","author":"Apalla","year":"2021","journal-title":"Dermatol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1159\/000491599","article-title":"Neurosarcoidosis Following Immune Checkpoint Inhibition","volume":"11","author":"Dunn-Pirio","year":"2018","journal-title":"Case Rep Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-018-0390-2","article-title":"Delayed Onset of Neurosarcoidosis After Concurrent Ipilimumab\/Nivolumab Therapy","volume":"6","author":"Tan","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1159\/000484596","article-title":"Pulmonary Sarcoidosis Activation Following Neoadjuvant Pembrolizumab Plus Chemotherapy Combination Therapy in a Patient With Non-Small Cell Lung Cancer: A Case Report","volume":"10","author":"Fakhri","year":"2017","journal-title":"Case Rep Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/cyt.12740","article-title":"Diagnostic Yield of Broncho-Alveolar Lavage for Pembrolizumab Induced Sarcoid-Like Reaction of the Lung","volume":"30","author":"Grosse","year":"2019","journal-title":"Cytopathol: Off J Br Soc Clin Cytol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1159\/000480155","article-title":"EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment From Tumor Progression in Non-Small Cell Lung Cancer","volume":"94","author":"Lainez","year":"2017","journal-title":"Respiration Int Rev Thorac Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-020-01667-0","article-title":"Particular Findings on Lung CT in Patients Undergoing Immunotherapy for Bronchogenic Carcinoma","volume":"132","author":"Beer","year":"2020","journal-title":"Wiener Klin Wochenschr"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1159\/000492383","article-title":"Sarcoid-Like Granulomatosis Induced by Nivolumab Treatment in a Lung Cancer Patient","volume":"11","author":"Noguchi","year":"2018","journal-title":"Case Rep Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e00542","DOI":"10.1002\/rcr2.542","article-title":"Durvalumab Induced Sarcoid-Like Pulmonary Lymphadenopathy","volume":"8","author":"Sanderson","year":"2020","journal-title":"Respirol Case Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04993-7","article-title":"68ga-DOTA-TATE PET\/CT Imaging for Differentiating a Sarcoid-Like Reaction From Progression Following Immunotherapy in a Triple-Negative Breast Carcinoma Patient","volume":"48","author":"Deleu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13386","article-title":"Sarcoidosis-Like Reaction in Metastatic Triple Negative Breast Cancer Treated by Anti-PD-L1","volume":"25","author":"Lafon","year":"2019","journal-title":"Breast J"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-216217","article-title":"Systemic Sarcoidosis First Manifesting in a Tattoo in the Setting of Immune Checkpoint Inhibition","author":"Kim","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001758","article-title":"Nivolumab-Induced Development of Pulmonary Sarcoidosis in Renal Cell Carcinoma","volume":"42","author":"Zhang","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw125","article-title":"Pulmonary Sarcoidosis Induced by the Anti-PD1 Monoclonal Antibody Pembrolizumab","volume":"27","author":"Cousin","year":"2016","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3941\/jrcr.v5i1.553","article-title":"Co-Existing Sarcoidosis Confounds the Staging of Bilateral Renal Cell Carcinoma","volume":"5","author":"Willis","year":"2011","journal-title":"J Radiol Case Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatol (Baltimore Md)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-Related Sarcoidosis Observed in Combination Ipilimumab and Nivolumab Therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of Liver Injury Induced by Cancer Immunotherapy Using Immune Checkpoint Inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.824308\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T14:31:11Z","timestamp":1646922671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.824308\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":70,"alternative-id":["10.3389\/fonc.2022.824308"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.824308","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"article-number":"824308"}}